Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Update Il y a 4 ans
Reference: NCT01683110

Woman and Man

Extract

The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.


Inclusion criteria

  • Medullary Thyroid Cancer

Links